Spots Global Cancer Trial Database for A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
The following info and data is provided "as is" to help patients around the globe.
We do not endorse or review these studies in any way.
Trial Identification
Brief Title: A Study to Evaluate Nivolumab in the Treatment of Early Stage Esophageal or Gastroesophageal Cancer
Official Title: Prospective Evaluation of Nivolumab in Adjuvant Esophageal Carcinoma/Gastroesophageal Junction Carcinoma: A Non-interventional Study
Study ID: NCT05780736
Interventions
Study Description
Brief Summary: The purpose of this study is to describe the effectiveness and use of nivolumab after surgery in participants with early stage (Stage II/III) Esophageal Cancer/Gastroesophageal Junction Cancer (EC/GEJC).
Detailed Description:
Eligibility
Minimum Age: 18 Years
Eligible Ages: ADULT, OLDER_ADULT
Sex: ALL
Healthy Volunteers: No
Locations
University Of Louisville, Louisville, Kentucky, United States
William Beaumont Army Medical Center, Fort Bliss, Texas, United States
The University Of Texas, Houston, Texas, United States
Baylor Scott and White Health, Temple, Texas, United States
Universitätsklinikum Tübingen, Tübingen, Baden-Württemberg, Germany
Klinikum Kassel, Kassel, Hessen, Germany
Local Institution - 0022, Offenbach, Hessen, Germany
Alexianer, Maria-Hilf-Krankenhaus, Essen, Nordrhein-Westfalen, Germany
Oncologianova GmbH, Recklinghausen, Nordrhein-Westfalen, Germany
Local Institution - 0006, Mainz, Rheinland-Pfalz, Germany
Local Institution - 0032, Bonn, Saarland, Germany
CaritasKlinikum Saarbruecken., Saarbruecken, Saarland, Germany
Klinikum Chemnitz Ggmbh, Chemnitz, Sachsen, Germany
BAG Freiberg-Richter, Jacobash, Illmer, Wolf, Dresden, Sachsen, Germany
Contact Details
Name: Bristol-Myers Squibb
Affiliation: Bristol-Myers Squibb
Role: STUDY_DIRECTOR
Take Control of Your Skin and Body Changes Today.
Try out Spots for free, set up only takes 2 mins.
Join others from around the world:
